Tscan Therapeutics Long Term Debt

As of the most recent data (June 2026), TCRX shows a long-term debt of $71M. That compares with $58M in the prior-year period — up 23.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TCRX's long-term debt is now $71M (was $58M) — a 23.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Tscan Therapeutics is outperforming or lagging.

Tracking TCRX's long-term debt over time shows whether Tscan Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $71M That compares with $58M in the prior-year period — up 23.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Tscan Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $71M) with ownership activity and broader fundamentals.

Tscan Therapeutics's long-term debt is $71M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.